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Background Few studies have evaluated medication adherence among older vs younger individuals with bipolar disorder
(BPD). We compared adherence with antipsychotic medication among older (age 60 and older) and younger individuals
using a large case registry (n¼ 73,964).
Methods Adherence was evaluated using the medication possession ratio (MPR) for patients receiving antipsychotic
medication.
Results Twenty six thousand five hundred and thirty younger individuals (mean age 46.9) and 6,461 older individuals
(mean age 69.2) were prescribed antipsychotic medication. Among older individuals, 61.0% (n¼ 3,350) were fully adherent,
while 19.0% (n¼ 1,043) were partially adherent and 20.0% (n¼ 1,098) were non-adherent. Among younger individuals,
49.5% (n¼ 10,644) were fully adherent, while 21.8% (n¼ 4,680) were partially adherent, and 28.7% (n¼ 6,170) were
non-adherent. As with younger patients, comorbid substance abuse and homelessness predicted non-adherence among older
patients with BPD.
Conclusion Older individuals with BPD were more adherent with antipsychotic medications compared to younger
individuals. However, a substantial proportion (approximately 39%) of older patients with BPD still have difficulties with
adherence. Copyright # 2007 John Wiley & Sons, Ltd.key words—treatment adherence; antipsychotic medications; bipolar disorder; elderly; geriatricINTRODUCTION:
An emerging literature has identified treatment
non-adherence as a pervasive problem that leads to
illness relapse, hospitalization and other negative
sequelae (Perlick et al., 2004). Studies evaluating
medication non-adherence among patients with BPD
found median rates of 41% (Lingam and Scott, 2002)*Correspondence to: Dr M. Sajatovic, Department of Psychiatry,
University Hospitals of Cleveland, 11100 Euclid Avenue,
Cleveland, OH 44106, USA. E-mail: martha.sajatovic@uhhs.com
Copyright # 2007 John Wiley & Sons, Ltd.and 42% (Perlick et al., 2004). Medication adherence
is a complex phenomenon that appears to be in-
fluenced by a number of patient, provider, and
environmental factors (Aagaard et al., 1988; Aagaard
and Vestergaard, 1990; Colom and Vieta, 2002; Berk
et al., 2004). Patient characteristics that appear to
be associated with adherence in BPD include
age, marital status, gender, and educational level
(Aagard et al., 1988; Lingam and Scott, 2002;
Berk et al., 2004). Concurrent psychiatric disorders
also appear to influence adherence (Aagaard and
Vestergaard, 1990; Keck et al., 1997; Perlick et al.,Received 2 August 2006
Accepted 4 January 2007
treatment adherence with antipsychotic in bpd 9932004). However, few studies have evaluated older
vs younger individuals with BPD with respect
to treatment adherence. Additionally, there is limited
information on adherence with antipsychotic medi-
cations, a class of drugs that is being used with
increasing frequency to treat bipolar illness. Using a
large case registry (n¼ 73,964), we examined adher-
ence with antipsychotic medication among veterans
with BPDwithin a one-year period [Federal Fiscal Year
2003 (FY03), 1 October 2002–30 September 2003].
The aim of the study was to compare treatment




Registry patients were identified using the VA’s
National Psychosis Registry (NPR), which regularly
incorporates data from the VA Patient Treatment File
(PTF), census data files, and Outpatient Care Files
(OPC) and the VA Pharmacy Benefits Management
Group. We identified patients with bipolar diagnosis in
the NPR using ICD9-CM codes 296.0, 296.1, 296.4,
296.5, 296.6, 296.7, and 296.8. Individuals were
included if they had at least one qualifying diagnosis
during Federal Fscal Year 2003 (FY03). In the event
that patients received more than one diagnosis over
time, individuals were assigned to the diagnosis which
appeared in the greatest number of episodes of care.
Ties were resolved using a rank ordering of: (1)
schizophrenia; (2) bipolar disorder; and (3) other
psychosis. A full report of the Psychosis Registry may
be viewed at: http://www.va.gov/annarbor-hsrd.
Measurement of adherence
Medication adherence was evaluated using the
medication possession ratio (MPR) for patients
receiving any antipsychotic medication. The MPR is
the ratio of the ‘number of days supply of medication
that a patient has received’ to the ‘number of days
supply that they should have received’ had they been
taking medication as prescribed. An MPR of 1 or
100% indicates that the patient has received all the
medication needed to take their antipsychotic medi-
cation as prescribed, whereas an MPR of 0.5% or 50%
indicates that the patient has received medication
sufficient to take only half of the prescribed dose.
The MPR was calculated among patients with at
least 90 outpatient days of observation during the
fiscal year. The MPR was calculated for the timeCopyright # 2007 John Wiley & Sons, Ltd.period of FY03 following the date of the patient’s first
antipsychotic medication fill of the year. Days spent
in institutional settings were subtracted from
the numbers of days supply the patient ‘should
have received’ in order to take their medication
as prescribed. MPR calculations were limited to
individuals who were taking no more than two
antipsychotic medications during the fiscal year. In
cases where an individual was on two antipsychotic
medications, a weighted average of the two MPRs
was calculated. The MPR, a measure of prescription
refills, has been widely utilized in both medical and
psychiatric settings as a proxy measure of treatment
adherence (Al-Zakwani et al., 2003; Hertz et al., 2005;
Patel et al., 2005; Sanchez et al., 2005; Yu et al.,
2005), including assessment of adherence in popu-
lations with serious mental illness, and in bipolar
populations specifically (Valenstein et al., 2002;
Gianfrancesco et al., 2006).
Antipsychotics prescribed in the VA during FY03
were conventional antipsychotic agents as well as the
atypical agents clozapine, risperidone, olanzapine,
quetiapine, ziprasidone and aripiprazole. Long-acting
injectable medications and medications prescribed for
use in inpatient settings were not included in analysis.
Adherence intensity
Patients’ degree of adherence was evaluated in three
clinically relevant categories. Individuals who were
fully adherent with antipsychotic medication had
MPRs greater than 0.8. Individuals who were partially
adherent with antipsychotic medication had MPRs of
more than 0.5 and less than or equal to 0.8. Individuals
who were considered to be non-adherent with
medication had MPRs of less than or equal to
0.5. Unlike some other previous reports (Al-Zakwani
et al., 2003), a maximum ratio of 1 was not applied, as
this would bias comparisons against agents with a
relatively high adherence intensity. While MPRs
greater than 1 may also reflect over-prescribers
(Gilmer et al., 2004) this cannot be determined solely
from claims data. For example, MPRs greater than
1 were possible in cases where prescriptions may not
have been completely used due to interim changes in
dosage.
Statistical analysis
Descriptive statistics were used to characterize
demographic and clinical characteristics of all patients
with BPD. A multiple logistic model was used to
compare characteristics of older vs younger patientsInt. J. Geriatr. Psychiatry 2007; 22: 992–998.
DOI: 10.1002/gps
994 m. sajatovic ET AL.with BPD. Multinomial multiple logistic regression
models compared characteristics of patients with
full or partial adherence to patients who were non-
adherent to antipsychotic medication, controlling for
the effects of gender, age, race/ethnicity, marital
status, previous psychiatric hospitalization, post-
traumatic stress disorder (PTSD), homelessness,
and concurrent substance abuse. PTSD and substance
abuse were selected as covariates of particular
relevance given the overwhelmingly male sample
and the fact that relatively high rates of combat-related
PTSD are seen in veteran populations. Characteristics
associated with adherence were examined separately
for the younger and older age groups. In addition, a
model including both age groups was analyzed to
examine interactions between age group and demo-
graphic and clinical variables, adjusting the sig-
nificance tests for multiple comparisons. Wilcoxon
tests were used to compare mean MPRs for patients
receiving one vs two antipsychotics, for patientsTable 1. Characteristics of veterans with bipolar disorder in FY03,







Number of patients 73,964 56,572 (76.5)
Mean age (SD) 52.3 (12.5) 47.0 (8.3)
Gender
Male 65,212 (88.2) 48,559 (85.8)
Female 8,752 (11.8) 8,013 (14.2)
Ethnicity
White 46,251 (62.5) 34,395 (60.8)
Black 7,694 (10.4) 6,904 (12.2)
Hispanic 2,249 (3.0) 1,814 (3.2)
American Indian 239 (0.3) 216 (0.4)
Asian 172 (0.2) 142 (0.3)
Unknown 17,359 (23.5) 13,101 (23.2)
Marital status
Never married 15,386 (21.0) 13,637 (24.3)
Married 27,651 (37.7) 18,813 (33.6)
Divorced/separated 27,751(37.9) 22,619 (40.4)
Widowed 2,497 (3.4) 949 (1.7)
Substance use disorder
Yes 23,484 (31.8) 21,152 (37.4)
No 50,480 (68.3) 35,420 (62.6)
PTSD diagnosis
Yes 15,721 (21.3) 13,921 (24.6)
No 58,243 (78.8) 42,651 (75.4)
Homelessness
Yes 10,176 (13.8) 9,447 (16.7)
No 63,788 (86.2) 47,125 (83.3)
Psychiatric hospitalization
in FY02
Yes 10,236 (13.8) 8,689 (15.4)
No 63,724 (86.2) 47,883 (84.6)
*Comparing mean age between groups: 47.0 vs 69.5.
Copyright # 2007 John Wiley & Sons, Ltd.receiving atypical vs conventional antipsychotics,
for patients receiving clozapine vs other atypical
antipsychotics, and for older vs younger patients.
RESULTS
There were 56,572 (76.5% of the total bipolar group)
individuals under age 60 and 17,388 (23.5%) individ-
uals age 60 or older. Compared to younger individuals,
older individuals were more likely to be Caucasian
(Wald x2¼ 128.6, df¼ 1, p< 0.0001) and married
(Wald x2¼ 149.7, df¼ 1, p< 0.0001). Younger indi-
viduals were more likely to have comorbid substance
abuse (Wald x2¼ 511.5, df¼ 1, p< 0.0001), comorbid
PTSD (Wald x2¼ 420.2, df¼ 1, p< 0.0001) and be
homeless (Wald x2¼ 95.6, df¼ 1, p< 0.0001) com-
pared to older individuals (Table 1). There were 26,530
(46.9%) individuals prescribed antipsychotic medi-
cations among the younger group (mean age 46.9,







Test of significance between groups
(controlling for other covariates)
17,388 (23.5)
69.5 (7.1) Wilcoxon Test Z¼ 199.8, p< 0.0001*
16,650 (95.8) Wald x2¼ 300.3, p< 0.0001, df¼ 11
738 (4.2)










2,331 (13.4) Wald x2¼ 511.5, p< 0.0001, df¼ 11
15,057 (86.6)
1,800 (10.4) Wald x2¼ 420.2, p< 0.0001, df¼ 1
15,588 (89.7)
729 (4.2) Wald x2¼ 95.6, p< 0.0001, df¼ 1
16,659 (95.8)
1,547 (8.9) Wald x2¼ 0.6, p¼ 0.4333, df¼ 1
15,841 (91.1)
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df¼ 1, p< 0.0001).
Among younger adults prescribed antipsychotics,
49.5% (n¼ 10,644) were fully adherent, while 21.8%
(n¼ 4,680) were partially adherent, and 28.7%
(n¼ 6,170) were non-adherent (Table 2). Among
older adults prescribed antipsychotics, 61.0% (n¼
3,350) were fully adherent, while 19.0% (n¼ 1,043)
were partially adherent and 20.0% (n¼ 1,098) were
non-adherent (Table 3). Non-adherent older adults
were more likely to have substance abuse [Odds Ratio
(OR)¼ 1.38, 95% Confidence Intervals (CI):1.13,
1.68] and be homeless (OR¼ 1.44, 95%CI:1.05, 1.97)
compared to older adults who were fully or partially
adherent, while non-adherent younger adults were
more likely to be of minority ethnicity (OR¼ 1.49,
95% CI:1.38, 1.61), have comorbid substance abuse
(OR¼ 1.30 95% CI:1.20, 1.40) and be homeless
(OR¼ 1.53, 95% CI:1.39, 1.67) compared to younger





Number of patients 10,644 (49.5) 4,680 (
Mean age (SD) 48.0 (7.6) 46.9 (
Gender
Male 9,137 (85.8) 4,011 (
Female 1,507 (14.2) 669 (
Ethnicity
White 7,509 (70.6) 3,027 (
Black 1,000 (9.4) 706 (
Hispanic 372 (3.5) 168 (
American Indian 49 (0.5) 16 (
Asian 26 (0.2) 8 (
Unknown 1,688 (15.9) 755 (
Marital status
Never married 2,555 (24.2) 1,118 (
Married 3,735 (35.3) 1,538 (
Divorced/separated 4,111 (38.9) 1,921 (
Widowed 168 (1.6) 80 (
Substance use disorder
Yes 3,554 (33.4) 1,921 (
No 7,090 (66.6) 2,759 (
PTSD diagnosis
Yes 2,905 (27.3) 1,390 (
No 7,739 (72.7) 3,290 (
Homelessness
Yes 1,213 (11.4) 782 (
No 9,431 (88.6) 3,898 (
Psychiatric hospitalization in FY02
Yes 2,071 (19.5) 1,027 (
No 8,573 (80.5) 3,653 (
aAdherent with >80% of medication.
bAdherent with >50–80% of medication.
cAdherent with less than or equal to 50% of medication.
Copyright # 2007 John Wiley & Sons, Ltd.interaction effects on adherence between age group
and gender, race/ethnicity, marital status, previous
psychiatric hospitalization, homelessness, comorbid
PTSD, and substance abuse were also examined. With
the exception of race/ethnicity, these interactions were
non-significant, suggesting that demographic and
clinical factors have similar associations with adher-
ence across age groups. However, the race/ethnicity
and age-group interaction was significant (Wald
x2¼ 22.0, df¼ 2, p< 0.0001). This indicates that
being in the older age group was associated with a
greater increase in antipsychotic adherence among
African Americans than among white patients
(OR¼ 1.58, 95% CI:1.17, 2.14).
Table 4 demonstrates adherence intensity for
individuals with BPD. Younger individuals had a
mean MPR on any antipsychotic of 0.74 (0.37),
while older individuals had a mean MPR of 0.82
(0.34) (Wilcoxon Test, Z¼ 14.4, p< 0.0001). The





Test of significance between groups
(controlling for other covariates)
21.8) 6,170 (28.7)
8.0) 45.6 (8.6) Wald x2¼ 150.4, p< 0.0001, df¼ 1
85.7) 5,287 (85.7) Wald x2¼ 3.2, p¼ 0.0726, df¼ 1
14.3) 883 (14.3)










41.1) 2,742 (44.4) Wald x2¼ 46.7, p< 0.0001, df¼ 1
59.0) 3,428 (55.6)
29.7) 1,776 (28.8) Wald x2¼ 3.5, p¼ 0.0629, df¼ 1
70.3) 4,394 (71.2)
16.7) 1,286 (20.8) Wald x2¼ 81.1, p< 0.0001, df¼ 1
83.3) 4,884 (79.2)
21.9) 1,354 (21.9) Wald x2¼ 0.3, p¼ 0.5674, df¼ 1
78.1) 4,816 (78.1)
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Test of significance between groups
(controlling for other covariates)
Number of patients 3,350 (61.0) 1,043 (19.0) 1,098 (20.0)
Mean age (SD) 69.2 (6.9) 69.2 (7.0) 69.0 (7.3) Wald x2¼ 0.1, p¼ 0.8108, df¼ 1
Gender
Male 3,181 (95.0) 993 (95.2) 1,042 (94.9) Wald x2¼ 0.1, p¼ 0.7089, df¼ 1
Female 169 (5.0) 50 (4.8) 56 (5.1)
Ethnicity
White 2,473 (73.8) 718 (68.8) 800 (72.9) Wald x2¼ 0.4, p¼ 0.5029, df¼ 1
Black 168 (5.0) 65 (6.2) 64 (5.8)
Hispanic 110 (3.3) 47 (4.5) 29 (2.6)
American Indian 5 (0.2) 2 (0.2) 0
Asian 4 (0.1) 2 (0.2) 3 (0.3)
Unknown 590 (17.6) 209 (20.0) 202 (18.4)
Marital status
Never married 368 (11.0) 92 (8.9) 106 (9.7) Wald x2¼ 0.6, p¼ 0.4581, df¼ 1
Married 1,673 (50.2) 508 (49.2) 512 (46.9)
Divorced/separated 973 (29.2) 332 (32.2) 384 (35.2)
Widowed 318 (9.5) 100 (9.7) 89 (8.2)
Substance use disorder
Yes 459 (13.7) 154 (14.8) 215 (19.6) Wald x2¼ 10.1, p¼ 0.0015, df¼ 1
No 2,891 (86.3) 889 (85.2) 883 (80.4)
PTSD diagnosis
Yes 404 (12.1) 113 (10.8) 139 (12.7) Wald x2¼ 0.3, p¼ 0.5914, df¼ 1
No 2,946 (87.9) 930 (89.2) 959 (87.3)
Homelessness
Yes 114 (3.4) 56 (5.4) 75 (6.8) Wald x2¼ 5.2, p¼ 0.0225, df¼ 1
No 3,236 (96.6) 987 (94.6) 1,023 (93.2)
Psychiatric hospitalization in FY02
Yes 493 (14.7) 151 (14.5) 180 (16.4) Wald x2¼ 0.3, p¼ 0.5693, df¼ 1
No 2,857 (85.3) 892 (85.5) 918 (83.6)
aAdherent with >80% of medication.
bAdherent with >50–80% of medication.
cAdherent with less than or equal to 50% of medication.
996 m. sajatovic ET AL.both older (91.9%) and younger (95.4%) groups
received atypical antipsychotics. MPRs were higher
for patients on two antipsychotics compared to those
taking single antipsychotics for both younger indi-
viduals (Z¼ 6.1, p< 0.0001) and older individuals
(Z¼ 2.6, p¼ 0.0082). For individuals on only one
antipsychotic, MPRs were higher for conventional
antipsychotics compared to atypical antipsychotics for
both younger (Z¼ 5.7, p< 0.0001) and older (Z¼ 2.6,
p¼ 0.0094) individuals.
DISCUSSION
In this large sample, antipsychotic medications were
prescribed less often to treat older individuals with
BPD (37.2%), compared to younger individuals with
BPD (46.9%). In common with earlier reports on
treatment adherence with traditional mood stabilizers,
older adults with BPD were more adherent with
antipsychotic medications compared to younger adults
with BPD (Perlick et al., 2004). Preliminary work byCopyright # 2007 John Wiley & Sons, Ltd.this group of investigators (Valenstein and Sajatovic,
in press) suggests that non-adherence rates among
bipolar populations appear rather similar across
compounds including lithium, anticonvulsants and
antipsychotic drugs. However, approximately 39% of
older adults had adherence difficulties, indicating that
this remains a pressing clinical issue for geriatric
populations. As with younger adults, substance abuse
and being homeless predicted non-adherence among
older adults with BPD. It has been reported that
younger and older bipolar populations have cognitive
impairments (Nehra et al., 2006; Robinson et al.,
2006; Young et al., 2006) that potentially could impact
treatment adherence. Older adults may be more likely
than younger individuals to have other individuals
such as family re-filling their medications, thus
contributing at least in part, to their slightly greater
adherence rates.
The majority of bipolar patients prescribed anti-
psychotic medications received atypical agents.
Clearly, atypical antipsychotic medications haveInt. J. Geriatr. Psychiatry 2007; 22: 992–998.
DOI: 10.1002/gps
Table 4. Adherence with antipsychotic medication among individuals with bipolar disorder
<60 years 60 years Wilcoxon Test of
significance between








All veterans with bipolar disorder on
any antipsychotic with MPR
21,494 (38.0) 0.74 (0.37) 5,491 (31.6) 0.82 (0.34) Z¼ 14.4, p< 0.0001
Individuals on conventional
antipsychotic
1,700 (7.9) 0.81 (0.34) 657 (12.0) 0.87 (0.31) Z¼ 4.2, p< 0.0001
Individuals on atypical
antipsychotics
20,514 (95.4) 0.74 (0.37) 5,044 (91.9) 0.81 (0.35) Z¼ 13.6, p< 0.0001
Clozapine 29 0.85 (0.24) 9 0.81 (0.32) Z¼0.2, p¼ 0.8637
Risperidone 6,720 0.73 (0.36) 1,622 0.79 (0.35) Z¼ 6.2, p< 0.0001
Olanzapine 8,776 0.73 (0.36) 2,508 0.82 (0.33) Z¼ 11.9, p< 0.0001
Quetiapine 7,410 0.76 (0.38) 1,400 0.83 (0.37) Z¼ 6.2, p< 0.0001
Ziprasidone 965 0.76 (0.38) 104 0.85 (0.34) Z¼ 2.2, p¼ 0.0293
Aripiprazole 114 0.79 (0.39) 22 0.75 (0.33) Z¼0.6, p¼ 0.5349
Individuals on a single antipsychotic
medication
17,261 (80.3) 0.73 (0.37)a 4,655 (84.7) 0.81 (0.34)b Z¼ 13.6, p< 0.0001
Individuals on two antipsychotic
medications
4,233 (19.7) 0.77 (0.36) 836 (15.2) 0.85 (0.34) Z¼ 5.6, p< 0.0001
For individuals on only one AP:
Atypical 16,294 (94.4) 0.73 (0.37)c 4213 (90.5) 0.81 (0.35)d Z¼ 12.8, p< 0.0001
Conventional 967 (5.6) 0.80 (0.33) 442 (9.5) 0.86 (0.31) Z¼ 12.8, p¼ 0.0010
Clozapine 19 (0.12) 0.90 (0.15)e 7 (0.17) 0.90 (0.14)f Z¼ 0.1, p¼ 0.9539
Other atypicals 16,275 (99.9) 0.73 (0.37) 4206 (99.8) 0.81 (0.35) Z¼ 12.8, p< 0.0001
asingle antipsychotic vs two antipsychotics: Wilcoxon Test, Z¼ 6.1, p< 0.0001.
bsingle antipsychotic vs two antipsychotics: Wilcoxon Test, Z¼ 2.6, p¼ 0.0082.
catypical vs conventional APs: Wilcoxon Test, Z¼ 5.7, p< 0.0001.
datypical vs conventional APs: Wilcoxon Test, Z¼ 2.6, p¼ 0.0094.
eclozapine vs other atypicals: Wilcoxon Test, Z¼ 1.9, p¼ 0.0545.
fclozapine vs other atypicals: Wilcoxon Test, Z¼ 0.4, p¼ 0.6681.
treatment adherence with antipsychotic in bpd 997assumed an important place in the treatment of
individuals with bipolar illness across the age span.
Individuals prescribed a single atypical antipsychotic
agent in both older and younger groups were less
adherent with treatment compared to individuals
prescribed a single typical agent. However, the
group of individuals on typical agent monotherapy
represented a small proportion (approximately 5% of
younger patients, and 10% of older patients) of all
patients. Possibly, individuals on typical antipsycho-
tics represent a sub-group of individuals who have
both good response and tolerance to these older
agents. Clinicians and patients may be reluctant to
switch from therapies that appear to be working
well. Interestingly, treatment adherence appears
better with two antipsychotic agents compared to
monotherapy in both older and younger individuals.
This has been observed in other bipolar populations
(Sajatovic et al., 2006) in a prospective mixed-age
study. It is not clear if more adherent patients are being
more aggressively treated, or alternatively, if more
aggressive use of atypical antipsychotic agents
actually promotes better treatment adherence amongCopyright # 2007 John Wiley & Sons, Ltd.patients with bipolar disorder. Clinicians may treat
patients with two agents only if they are convinced
that patients are adherent with monotherapy, while at
the same time avoiding use of complicated (multi-
drug) regimens for individuals with a history of
non-adherence.
Limitations of this study include the fact that
prescription refills may not actually reflect medication
ingestion, and that the elderly group may represent
a survivor cohort characterized by long-term adher-
ence. The ‘younger’ sample in this analysis averaged
48 years of age. Differences among older vs younger
bipolar groups might be more pronounced among
bipolar adults in their 20s and 30s vs an older
population. Additionally, since this was a VA sample,
results cannot necessarily be extrapolated to a more
gender heterogenous bipolar population.
It has been suggested that focused attention to
treatment adherence may improve adherence (Scott
and Tacchi, 2002). Interventions to enhance treatment
adherence among older adults with BPD should
consider those who are at greatest risk of non-
adherence—individuals with comorbid substance use,Int. J. Geriatr. Psychiatry 2007; 22: 992–998.
DOI: 10.1002/gps
998 m. sajatovic ET AL.and those with poor psychosocial supports. Add-
itionally, older individuals with BPD are noted to
have substantial deficits in knowledge regarding
medications and treatment (Schaub et al., 2001) and
are likely to benefit from interventions that will
improve illness understanding.
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